Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PROCEPT BioRobotics Corp (PRCT)

PROCEPT BioRobotics adds Dr. Michael Mack to board, expanding it to ten members

Neutral Impact 2 of 5 leadership Written later

PROCEPT BioRobotics increased its board from nine to ten members and appointed Dr. Michael Mack, a cardiac surgeon, as a director effective immediately. The Board determined Mack is independent under SEC and Nasdaq rules, which adds an independent director with extensive thoracic surgery and medical society leadership experience.

Key points

  • Dr. Michael Mack appointed as Class II director; term expires at the 2029 annual meeting
  • Board size increased from nine members to ten effective October 2, 2026
  • Board determined Mack is independent under SEC and Nasdaq rules
  • Mack will receive non-employee director compensation and sign the Company's standard indemnification agreement

The filing

CompanyPROCEPT BioRobotics Corp (PRCT)
Form8-K, current report
Filed with the SECOct 2, 2026, 4:46 PM ET
Accession number0001628280-26-064586

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.